Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Active negotiation
Manufacturer:
Idorsia Pharmaceuticals Canada Ltd.
Indication:
Insomnia
Last updated:
February 11, 2026
Status:
Under consideration for negotiation
Manufacturer:
Incyte Biosciences Canada Corporation
Indication:
in combination with lenalidomide for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).
Last updated:
February 6, 2026
Carvykti (ciltacabtagene autoleucel)
Status:
Active negotiation
Manufacturer:
Janssen Inc.
Indication:
For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
Last updated:
February 6, 2026
Carvykti (ciltacabtagene autoleucel)
Status:
Active negotiation
Manufacturer:
Janssen Inc.
Indication:
Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Last updated:
February 6, 2026
Status:
Concluded without agreement
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Idiopathic pulmonary fibrosis and PF-ILD
Last updated:
February 5, 2026
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Last updated:
February 3, 2026
Status:
Concluded without agreement
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
generalized pustular psoriasis (GPP)
Last updated:
February 3, 2026
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy
Last updated:
January 29, 2026
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.
Last updated:
January 29, 2026
Lazcluze and Rybrevant (lazertinib and amivantamab)
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
Last updated:
January 29, 2026